Related Experiment Video
Updated: Aug 7, 2026

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
Published on: October 6, 2015
Neuroleptic malignant syndrome in a patient with succinic semialdehyde dehydrogenase deficiency
Peter Neu1, S Seyfert, J Brockmöller
1Department of Psychiatry, Freie Universität Berlin, Eschenallee 3, 14050 Berlin, Germany. peter.neu@medizin.fu-berlin.de
Abstract:
A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol. We investigated the patient's serum for all frequent polymorphisms in cytochrome P450 2D6, assuming him to be a poor neuroleptic metabolizer. We will also discuss other potential mechanisms inducing this disturbance and its differential diagnoses.
Related Concept Videos
Depolarizing Blockers: Pharmocokinetics
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology
Hepatic Encephalopathy

